Key regions: France, Europe, United Kingdom, Brazil, India
The Oncology Drugs market in Chad has been steadily growing in recent years due to various factors.
Customer preferences: Customers in Chad prefer to purchase generic drugs due to their affordability. This preference for generic drugs has led to an increase in the consumption of oncology drugs in Chad. Additionally, customers in Chad are increasingly seeking out drugs that have a proven track record of success in treating cancer.
Trends in the market: The Oncology Drugs market in Chad has been growing due to the increasing prevalence of cancer in the country. This has led to an increase in demand for oncology drugs. Furthermore, the government of Chad has been investing in the healthcare sector, which has led to an increase in the availability of oncology drugs in the country.
Local special circumstances: Chad is a landlocked country, which means that it has limited access to ports. This has led to higher transportation costs for oncology drugs, which has made them more expensive in Chad than in other countries. Additionally, the lack of infrastructure in Chad has made it difficult for pharmaceutical companies to distribute their products in the country.
Underlying macroeconomic factors: The economy of Chad is heavily dependent on oil exports. The recent decline in oil prices has led to a decrease in government revenue, which has made it difficult for the government to invest in the healthcare sector. Furthermore, the political instability in the country has made it difficult for foreign investors to invest in the healthcare sector in Chad.In conclusion, the Oncology Drugs market in Chad has been growing due to the increasing prevalence of cancer in the country and the government's investment in the healthcare sector. However, the high transportation costs and lack of infrastructure in Chad have made it difficult for pharmaceutical companies to distribute their products in the country. Furthermore, the decline in oil prices and political instability in the country have made it difficult for the government to invest in the healthcare sector.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
